Compliance Certificate under Reg.74(5) of SEBI (DP) Regulation, 2018
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended 30 June 2025, as required under SEBI's Depositories and Participants Regulations, 2018. The certificate, issued by the company's Registrar and Transfer Agent Aarthi Consultants Private Limited, confirms that physical share certificates received for dematerialization were properly mutilated and cancelled within the stipulated 15-day timeframe. It also confirms that the depository's name has been substituted as the registered owner in company records. This is a standard procedural filing with no business or financial details.
No impact on shareholders or stock price. This is a routine regulatory compliance filing related to share dematerialization processes, submitted quarterly as mandated by SEBI rules.